Glenmark gets FDA nod for chlorzoxazone
Patients with muscle spasms and pain will soon have a new generic treatment option.
The Food and Drug Administration has cleared Glenmark’s chlorzoxazone tablets in dosage strengths of 375 mg and 750 mg.
This marks Glenmark’s first abbreviated new drug application approval from their new North American manufacturing facility based in Monroe, N.C.
The product has a market value of roughly $20.9 million, for the 12 months ended March 2020, according to IQVIA.